Skip to main content

Table 1 Demographics and baseline characteristics (Phase 1 and 2)

From: Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study

Parameter, n (%) Category/statistic Phase 1 (N = 19) Phase 2 (30 mcg/kg; N = 33)
Gender, n (%) Male 15 (79) 26 (79)
Female 4 (21) 7 (21)
Age in years, Median (range)   63 (48–77) 61 (46–75)
ECOG, n (%) 0 15 (79) 15 (45)
1 4 (21) 18 (55)
Prognostic risk category*, n (%) Low risk 12 (63) 17 (52)
Intermediate risk 7 (37) 16 (48)
Prior systemic treatment regimens for mRCC**, n (%) 0 10 (53) -
1 8 (42) 25 (76)
2 0 (0) 8 (24)
3 1 (5)  
Agents used for prior systemic therapy**, n (%) VEGFR-TKIs   
  Sunitinib 4 (21) 19 (58)
  Pazopanib   1 (3)
  Cediranib   1 (3)
mTOR Inhibitors   
  Temsirolimus   5 (15)
  Everolimus   2 (6)
Bevacizumab   3 (9)
Immunotherapy   
  IL-2 4 (21) 11 (33)
  Interferon   1 (3)
  Vaccine   3 (9)
  TLR-9 agonist 1 (5)  
  IL-2 gene therapy 1 (5)  
Other   
  Vinblastine   1 (3)
  ABT-510 1 (5)  
  1. *Based on Memorial Sloan Kettering Cancer Center (MSKCC) risk categorization.
  2. **Number of prior treatment regimens, could consist of a combination of agents.